Pediatric surgery international · 2025
Postoperative outcomes of robotic-assisted vs. laparoscopic pull-through surgery in pediatric Hirschsprung's disease: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Durazo Carla Isabella Miret, Frei Paloma, Go Stephanie Gail Giray, Ameenuthin Rafeeqa Binte, Baptista M J Marie Caragon, Diaz Francesca Gabriela Ocana, Reyes Yadelys Rodriguez, Ejinaka Sylvia Oluwafunmilayo, Shawish Abdulrahman Abdulkarim, Reyna Evelyn Saavedra, Srinivasan Saimuralidhar S, Moreno Stephani Carolina Salvatierra, Arruarana Victor Sebastan
Аннотация
Hirschsprung's disease (HSCR) is a congenital bowel disorder caused by absent enteric ganglion cells, often in neonates with intestinal obstruction. Minimally invasive surgical resection is the standard treatment. Robotic-assisted pull-through surgery (RAS) offers improved precision, but comparative data with laparoscopic-assisted surgery (LAS) is limited. This systematic review and meta-analysis evaluated postoperative outcomes between RAS and LAS in pediatric HSCR. Literature search was performed in PubMed/MEDLINE, Web of Science, Scopus, EMBASE, CINAHL, and Cochrane Library, following PRISMA guidelines. Random-effects meta-analysis with 95% confidence interval (CI) was conducted. Protocol was preregistered on PROSPERO (CRD420251033648). Four studies involving 291 pediatric patients (124 RAS, 167 LAS) were included. RAS demonstrated significantly lower blood loss (MD = - 2.66; 95% CI - 4.54 to - 0.80; p < 0.01) and higher hospitalization expenses (MD = 44,922.20; 95% CI 43,592.28-46,252.12; p < 0.01). LAS presented shorter postoperative feed times (MD = 1.00; 95% CI 0.16-1.84; p = 0.02). No significant differences were observed in other postoperative outcomes. RAS appears to be a safe alternative to LAS in pediatric HSCR. However, no definitive clinical advantage of RAS is confirmed. Further studies are warranted to clarify its role in pediatric colorectal surgery.